Press Releases
-
Advanced BioDesign accelerates ODYSSEY clinical trial with a new design following ABD-3001’s highly promising initial results in Acute Myeloid Leukemia
• Initial clinical data for ABD-3001 in AML have led French health authorities to approve a compassionate use program for the treatment. • Thanks to…
-
Advanced BioDesign: A new study published in the Journal of Cellular Molecular Medicine on the involvement of ALDH activity in r/r AML
Lyon (France), October 29, 2024 – Acute Myeloid Leukemia (AML) remains a major medical challenge despite recent advances in targeted molecular therapies. A recent study…
-
Advanced BioDesign announces exceptional first-in-human results for its innovative treatment against Acute Myeloid Leukemia
Lyon (France), June 4, 2024 – Advanced BioDesign, a biotech company specializing in the development of new therapeutic approaches to resistant cancers, has released the…
-
Advanced BioDesign joins forces with GTP Bioways to startmanufacturing of its innovative treatment for Acute MyeloidLeukemia (AML)
Lyon, Toulouse (France), March 27, 2024 – Advanced BioDesign, a biotech company specializing in the development of new therapeutic approaches to resistant cancers, and GTP…
Advanced BioDesign 